Back to results
US 2026/0097057 A1Published application
Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis
OwnerPhilip Amberyinventor
Life of this patent
Estimating the term…
Abstract
Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
Claims26
A method of treating liver fibrosis in a human patient who has chronic kidney disease (CKD), the method comprising administering to the patient a fixed-dose combination of zibotentan and dapagliflozin in an amount effective to treat the patient's liver fibrosis.
3-22. (canceled)
27-33. (canceled)
35-40. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.